Ozempic and Wegovy
Ozempic and Wegovy can cause serious vision loss in a rare side effect, health officials have warned.
The medicines regulator has ruled that the chemical in both drugs, semaglutide, increases the risk of a condition that causes sudden, painless vision loss in one eye.
The medicine, which is administered as a weekly injection, can interrupt blood flow to the front of the optic nerve and cause vision loss in a condition called non-arteritic anterior ischemic optic neuropathy (NAION).
Autoridades alertam: Ozempic e Wegovy podem causar risco raro de visão grave, e neste vídeo você vai entender exatamente o que isso significa na prática. Vamos explicar quais são os sintomas que merecem atenção, por que esse alerta surgiu, quem pode estar mais exposto e como se informar melhor antes de comprar ou iniciar o uso. Se você já utiliza ou está pensando em usar esses medicamentos, é essencial conhecer os sinais de alerta e saber quando procurar ajuda médica. Aqui você encontra uma análise clara, direta e baseada em informações atuais, sem alarmismo, mas com foco na sua segurança. Assista até o final para aprender como identificar mudanças na visão, quais exames podem ser recomendados e quais perguntas fazer ao seu médico. Informação é a melhor forma de prevenir riscos e tomar decisões conscientes sobre sua saúde.
It comes a week after the regulator issued a warning that the family of weight-loss drugs, known as GLP-1s, is linked to a potentially fatal pancreatic condition.
Novo Nordisk, the manufacturer of Ozempic, also saw its stock price plunge by almost a fifth on Wednesday after it revealed sales of its blockbuster jabs would fall this year amid increasing competition from rival drug Mounjaro.
Now, the Medicines and Healthcare products Regulatory Agency (MHRA) has issued new advice to those using semaglutide, which is called Wegovy for weight loss and Ozempic when prescribed to treat diabetes.
The update warns “of the very rare occurrence of non-arteritic anterior ischemic optic neuropathy”.
Patients who have experienced the condition describe it as a blurring or cloudiness of vision.
Potential risk ‘extremely small’ – Ozempic and Wegovy
The MHRA has urged anyone taking semaglutide to go to an eye casualty unit or A&E if they notice a change in eyesight, such as sudden impairment to their vision, or if their eyesight quickly deteriorates in one or both eyes.
Dr Alison Cave, the MHRA chief safety officer, said: “While the potential risk of NAION for patients prescribed semaglutide is extremely small, it is important that patients and healthcare professionals are alert to the associated symptoms.Related video: GLP-1 weight loss drugs do save lives, but here’s what people get wrong about them (Couch Glue)
Comprar Ozempic na farmácia online em Portugal pode parecer simples, mas há detalhes importantes que quase ninguém explica. Neste artigo, mostro um guia prático e direto sobre como comprar com segurança, como usar corretamente, qual a dosagem inicial de 0,25 mg, quais são os possíveis efeitos secundários e por que a orientação médica é tão importante. Se estás a pensar em usar Ozempic para controlo de peso ou gestão da diabetes, este conteúdo vai poupar-te tempo, dinheiro e possíveis problemas. Vais aprender a identificar farmácias online confiáveis, evitar fraudes, entender a prescrição e usar o medicamento da forma correta. Tudo explicado em linguagem simples, sem complicações e com dicas práticas que realmente funcionam. Assiste até ao fim para não cometeres erros comuns que muita gente comete ao comprar Ozempic online em Portugal.
GLP-1 weight loss drugs do save lives, but here’s what people get wrong about them
Current Time 0:02
/
Duration 3:10
0
“If you, or someone you care for, is taking semaglutide and you notice sudden loss of vision in one eye, then we advise you to urgently attend eye casualty – if available in your area – or A&E and report it via our yellow card scheme.”
Since 2018, the MHRA has been alerted to three reports linking NAION to the use of semaglutide.
Separate studies suggest the drug may affect up to one in 10,000.
Last week, the medicines regulator warned that using the drugs, known as GLP-1 receptor agonists, increased the risk of developing acute pancreatitis, which is when the pancreas becomes inflamed.
While the potential side effect was already known, the MHRA now believes those risks are more severe than first thought.
It urged weight-loss jab users to look out for symptoms, including extreme pain in the stomach and back, which do not go away.
It advised users of the drug to see a doctor immediately if they experience this, which may also occur alongside nausea and vomiting.
Recommended
Ozempic made me vomit five times a day, says Stephen Fry
Product information for healthcare professionals and patients regarding both of these risks has been updated as a result.
The MHRA has received more than 1,000 reports of patients developing an inflamed pancreas while taking the drug.
Although serious cases are rare, the reports have included 19 deaths and 24 cases of necrotising pancreatitis, in which tissue in the pancreas dies.
More than 1.6 million adults in England, Wales and Scotland are thought to have used drugs such as Wegovy and Mounjaro in the past year.
Weight-loss drugs work by mimicking the hormone GLP-1 to regulate blood sugar and insulin levels and were initially developed as a treatment for type 2 diabetes.